Affordable Access

Publisher Website

Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.

Authors
  • Liu, Yuan1, 2
  • Lear, Travis B1, 3
  • Verma, Manish4
  • Wang, Kent Zq4
  • Otero, P Anthony4
  • McKelvey, Alison C1
  • Dunn, Sarah R1
  • Steer, Erin4
  • Bateman, Nicholas W5
  • Wu, Christine5
  • Jiang, Yu6
  • Weathington, Nathaniel M1
  • Rojas, Mauricio1
  • Chu, Charleen T2, 4, 7, 8
  • Chen, Bill B1, 9
  • Mallampalli, Rama K1, 5, 10
Type
Published Article
Journal
JCI Insight
Publisher
American Society for Clinical Investigation
Publication Date
Jun 03, 2020
Volume
5
Issue
11
Identifiers
DOI: 10.1172/jci.insight.131834
PMID: 32493843
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Mitochondrial quality control is mediated by the PTEN-induced kinase 1 (PINK1), a cytoprotective protein that is dysregulated in inflammatory lung injury and neurodegenerative diseases. Here, we show that a ubiquitin E3 ligase receptor component, FBXO7, targets PINK1 for its cellular disposal. FBXO7, by mediating PINK1 ubiquitylation and degradation, was sufficient to induce mitochondrial injury and inflammation in experimental pneumonia. A computational simulation-based screen led to the identification of a small molecule, BC1464, which abrogated FBXO7 and PINK1 association, leading to increased cellular PINK1 concentrations and activities, and limiting mitochondrial damage. BC1464 exerted antiinflammatory activity in human tissue explants and murine lung inflammation models. Furthermore, BC1464 conferred neuroprotection in primary cortical neurons, human neuroblastoma cells, and patient-derived cells in several culture models of Parkinson's disease. The data highlight a unique opportunity to use small molecule antagonists that disrupt PINK1 interaction with the ubiquitin apparatus to enhance mitochondrial quality, limit inflammatory injury, and maintain neuronal viability.

Report this publication

Statistics

Seen <100 times